← Back to Search

Brain Imaging for Amphetamine Use Disorder

Phase 1
Waitlist Available
Led By Walter Ling, M.D.
Research Sponsored by National Institute on Drug Abuse (NIDA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
M/F, ages 21-50
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing whether changes in the brain caused by cocaine and methamphetamine dependence can be seen using PET scans.

Who is the study for?
This trial is for men and women aged 21-50 who meet the criteria for methamphetamine and nicotine dependence. Participants must agree to study conditions and sign informed consent. It excludes those with psychiatric disorders needing medication, seizure history, pregnant or nursing women, alcohol or sedative dependency, acute hepatitis, or other unsafe medical conditions.Check my eligibility
What is being tested?
The study aims to assess changes in the striatum's dopamine transporter (DAT) availability due to cocaine or methamphetamine use by using PET tracers WIN and FDOPA. It will compare these effects shortly after last drug use (3-5 days) and check if they persist after three months of abstinence.See study design
What are the potential side effects?
Since this trial involves diagnostic procedures rather than treatment interventions, typical side effects associated with medications are not a primary concern. However, participants may experience discomfort from imaging procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 50 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)Lead Sponsor
2,468 Previous Clinical Trials
2,619,348 Total Patients Enrolled
Walter Ling, M.D.Principal InvestigatorFriends Research Institute, Inc.
38 Previous Clinical Trials
4,118 Total Patients Enrolled

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00000350 — Phase 1
Amphetamine Use Disorder Research Study Groups:
Amphetamine Use Disorder Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00000350 — Phase 1
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00000350 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial cater to those aged 50 and over?

"Eligible participants for this medical trial will be between the ages of 21 and 50."

Answered by AI

Who is qualified to be a participant in this medical experiment?

"The requirements to enroll in this trial are an age range of 21 through 50 and a diagnosis of amphetamine abuse. Currently, 0 patients have been accepted into the study."

Answered by AI

Has this remedy been declared permissible by the FDA?

"Due to a lack of sufficient data, the safety rating for this treatment was assessed as a 1. This is because it is currently undergoing Phase 1 testing; thus, there's limited evidence regarding efficacy and security."

Answered by AI

Are there any opportunities for individuals to participate in this research?

"Clinicaltrials.gov suggests that this particular medical trial is not accepting any new participants at present; the original post was made on March 1st, 1999 and last updated January 10th 2017. Nevertheless, there are still over a thousand other studies recruiting volunteers right now."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
How old are they?
18 - 65
What site did they apply to?
Friends Research Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
1999. "Effects of Stimulant Dependence on Human Striatal Dopamine System - 15". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00000350.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top